The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $56.93

Today's change0.00 0.00%
Updated May 4 4:02 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $56.93

Today's change0.00 0.00%
Updated May 4 4:02 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S closed at (U.S.)$56.93.

Over the last five days, shares have gained 0.26% and are currently 1.30% off of the 52-week high. Shares have outperformed the S&P 500 by 16.13% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $56.93
  • High--
  • Low--
  • Bid / Ask(U.S.) $56.89 / (U.S.) $57.08
  • YTD % change+34.52%
  • Volume0
  • Average volume (10-day)1,549,775
  • Average volume (1-month)1,571,986
  • Average volume (3-month)1,705,037
  • 52-week range(U.S.) $41.72 to (U.S.) $57.68
  • Beta0.91
  • Trailing P/E37.94×
  • P/E 1 year forward31.55×
  • Forward PEG2.04×
  • Indicated annual dividend(U.S.) $0.76
  • Dividend yield1.33%
  • Trailing EPS(U.S.) $1.50
Updated May 4 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+29.82%

Based on its net profit margin of 29.82%, Novo Nordisk A/S is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.18%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue24,58522,24921,62920,343
Total other revenue--------
Total revenue24,58522,24921,62920,343
Gross profit20,58618,82317,95816,877
Total cost of revenue3,9993,4263,6713,466
Total operating expense15,42813,68012,89612,310
Selling / general / administrative7,7466,7696,3545,891
Research & development3,8653,6543,0753,168
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total-182-169-204-215
Operating income9,1578,5698,7338,033
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax8,3528,4548,9898,301
Income after tax6,5296,5006,9946,458
Income tax, total1,8231,9541,9951,843
Net income6,5296,5006,9946,458
Total adjustments to net income--------
Net income before extra. items6,5296,5006,9946,458
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items6,5296,5006,9946,458
Inc. avail. to common incl. extra. items6,5296,5006,9946,458
Diluted net income6,5296,5006,9946,458
Dilution adjustment0--0--
Diluted weighted average shares2,6302,6222,6372,653
Diluted EPS excluding extraordinary itemsvalue per share2.482.482.652.43
Dividends per sharevalue per share5.110.000.000.00
Diluted normalized EPSvalue per share2.482.482.652.43